HomeCompareFHLKX vs ABBV

FHLKX vs ABBV: Dividend Comparison 2026

FHLKX yields 3.04% · ABBV yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $83.1K in total portfolio value
10 years
FHLKX
FHLKX
● Live price
3.04%
Share price
$11.15
Annual div
$0.34
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.3K
Annual income
$369.82
Full FHLKX calculator →
ABBV
AbbVie Inc.
● Live price
3.18%
Share price
$208.80
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.4K
Annual income
$26,796.51
Full ABBV calculator →

Portfolio growth — FHLKX vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFHLKXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FHLKX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FHLKX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FHLKX
Annual income on $10K today (after 15% tax)
$258.43/yr
After 10yr DRIP, annual income (after tax)
$314.35/yr
ABBV
Annual income on $10K today (after 15% tax)
$270.72/yr
After 10yr DRIP, annual income (after tax)
$22,777.03/yr
At 15% tax rate, ABBV beats the other by $22,462.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FHLKX + ABBV for your $10,000?

FHLKX: 50%ABBV: 50%
100% ABBV50/50100% FHLKX
Portfolio after 10yr
$65.8K
Annual income
$13,583.16/yr
Blended yield
20.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FHLKX
No analyst data
Altman Z
-0.5
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+22.7% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FHLKX buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFHLKXABBV
Forward yield3.04%3.18%
Annual dividend / share$0.34$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$24.3K$107.4K
Annual income after 10y$369.82$26,796.51
Total dividends collected$3.4K$65.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FHLKX vs ABBV ($10,000, DRIP)

YearFHLKX PortfolioFHLKX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,004$304.04$11,568$447.80$564.00ABBV
2$12,087$312.67$13,518$654.97$1.4KABBV
3$13,254$320.98$16,000$967.77$2.7KABBV
4$14,511$328.94$19,240$1,448.28$4.7KABBV
5$15,863$336.57$23,597$2,202.04$7.7KABBV
6$17,317$343.87$29,655$3,414.72$12.3KABBV
7$18,880$350.84$38,402$5,425.87$19.5KABBV
8$20,560$357.48$51,587$8,884.00$31.0KABBV
9$22,363$363.81$72,455$15,089.50$50.1KABBV
10$24,298$369.82$107,366$26,796.51$83.1KABBV

FHLKX vs ABBV: Complete Analysis 2026

FHLKXStock

The fund is designed to assist investors in saving for future eligible medical expenses. Investing primarily in a combination of both actively and passively managed Fidelity bond and equity funds and affiliated and unaffiliated exchange-traded funds (collectively, underlying funds). Investing approximately 30% of the fund's assets in underlying equity funds and 70% of the fund's assets in underlying bond funds.

Full FHLKX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FHLKX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FHLKX vs SCHDFHLKX vs JEPIFHLKX vs OFHLKX vs KOFHLKX vs MAINFHLKX vs JNJFHLKX vs MRKFHLKX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.